purchase sotrovimab under the agreement. The European Medicines Agency (EMA) is now conducting a rolling regulatory review of the medicine. Sotrovimab is also listed in the European Commission’s portfolio of potential candidate therapies based on its Covid-19 Therapeutics Strategy.
George Katzourakis, senior vice president of GSK Europe expressed optimism about the new deal. He said, “This agreement with the European Commission represents a crucial step forward for treating cases of COVID-19 in participating EU Member States, as it enables access to sotrovimab for high-risk patients who have contracted the virus”. He added, “As the COVID-19 landscape continues to evolve and we meet new challenges – such as the Delta variant spreading across the globe – there remains an urgent need for treatment options to help those who do get sick to potentially avoid hospitalisation or death.”
According to the company, it has made deals with a number of governments throughout the world to distribute sotrovimab. The United States Food and Medicine Administration (FDA) has already granted the emergency use authorisation (EUA) to the drug for the treatment of mild-to-moderate Covid-19 in high-risk patients. Qatar, Kuwait, the United Arab Emirates, Singapore, and Bahrain have all approved it for emergency usage.
